bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1. Effects of long term pan-caspase inhibition on autophagy in myeloma cells. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
Authors: Rosebeck Shaun , Alonge Mattina M. , Kandarpa Malathi , Mayampurath Anoop , Volchenboum Samuel L. , Jasielec Jagoda , Dytfeld Dominik , Maxwell Sean P. , Kraftson Stephanie J. , McCauley Dilara , Shacham Sharon , Kauffman Michael , Jakubowiak Andrzej J.
Published: April 2023

Western blot analysis of markers for autophagy and apoptosis in MM1.S cells treated for the indicated time with pan-caspase inhibitor.
Supplementary Figures 1-5 and Supplementary Table 1 from Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
Authors: Bridgeman Victoria L. , Wan Elaine , Foo Shane , Nathan Mark R. , Welti Jonathan C. , Frentzas Sophia , Vermeulen Peter B. , Preece Natasha , Springer Caroline J. , Powles Thomas , Nathan Paul D. , Larkin James , Gore Martin , Vasudev Naveen S. , Reynolds Andrew R.
Published: April 2023

Supplementary Figure 1 Growth kinetics for all 786-0 xenografts included in the analysis from Figure 1; Supplementary Figure 2 Details of the in vitro angiogenesis assay; Supplementary Figure 3 Isolation of a sunitinib-refractory sub-line (786-0-R) from the parental 786-0 cell line; Supplementary Figure 4 Anti-angiogenic activity of sunitinib combined with trametinib within an in vitro tubule formation assay; Supplementary Figure 5 Quantification of tumor vessel density in treated tumors; Supplementary Table 1 Genotyping of the original patient sample and each generation of the PDX by STR typing
Supplemental Figure 3 from Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model
Authors: Sandulache Vlad C. , Chen Yunyun , Skinner Heath D. , Lu Tongtong , Feng Lei , Court Laurence E. , Myers Jeffrey N. , Meyn Raymond E. , Fuller Clifton D. , Bankson James A. , Lai Stephen Y.
Published: April 2023

Supplemental Figure 3. IR effects on cellular lactate and clonogenic survival are driven by ROS.
supplementary figure 6 from Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma
Authors: Noguchi Fumihito , Inui Shigeki , Fedele Clare , Shackleton Mark , Itami Satoshi
Published: April 2023

Supplementary Figure S6, related to Figure 6. The cytotoxicity enhancement of OXPHOSi elicited by acidity is distinct from TIS
supplementary figure 5 from Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma
Authors: Noguchi Fumihito , Inui Shigeki , Fedele Clare , Shackleton Mark , Itami Satoshi
Published: April 2023

Supplementary Figure S5, related to Figure 5. ROS scavenging synergizes with the cytotoxicity enhancement of OXPHOSi elicited by acidity
supplementary figure 4 from Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma
Authors: Noguchi Fumihito , Inui Shigeki , Fedele Clare , Shackleton Mark , Itami Satoshi
Published: April 2023

Supplementary Figure S4, related to Figure 4. Intracellular Ca2+ level is increased in melanoma cells after treatment with OXPHOSi at an acidic pHe, leading to cell death
supplementary figure 3 from Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma
Authors: Noguchi Fumihito , Inui Shigeki , Fedele Clare , Shackleton Mark , Itami Satoshi
Published: April 2023

Supplementary Figure S3, related to Figure 3. OXPHOS-inhibition causes the activation of caspase-dependent apoptosis at an acidic pHe
supplementary figure 2 from Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma
Authors: Noguchi Fumihito , Inui Shigeki , Fedele Clare , Shackleton Mark , Itami Satoshi
Published: April 2023

Supplementary Figure S2, related to Figure 2. Systemic buffering attenuates the anti-cancer effect of phenformin on B16F10 cells in vivo
Supplementary Video S2 from Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform
Authors: Zhang Yilin , Sriraman Shravan Kumar , Kenny Hilary A. , Luther Ed , Torchilin Vladimir , Lengyel Ernst
Published: April 2023

SKOV3-TR treated with LP(PCT)
Supplementary Materials and Methods, Table S1, Video legends, and Figure S1-5 from Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform
Authors: Zhang Yilin , Sriraman Shravan Kumar , Kenny Hilary A. , Luther Ed , Torchilin Vladimir , Lengyel Ernst
Published: April 2023

Table S1: Characterization of drug-loaded liposomes; Supplementary Figure S1: Liposome treatments reduced cell viability and inhibited cell migration; Supplementary Figure S2: Liposomes do not affect ovarian cancer cell adhesion/invasion in an organotypic 3 dimensional culture model; Supplement Figure S3: Tariquidar and paclitaxel co-loaded liposomes cause mitotic arrest in paclitaxel resistant cells; Supplementary Figure S4: Quantification of paclitaxel-mediated apoptotic events using laser scanning imaging cytometry; Supplementary Figure S5: Liposomal packaging of tariquidar does not affect metastatic growth in an orthotopic model of chemoresistant ovarian cancer.
Supplementary Figures from In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia
Authors: Hagemann Urs B. , Wickstroem Katrine , Wang Ellen , Shea Adam O. , Sponheim Kristine , Karlsson Jenny , Bjerke Roger M. , Ryan Olav B. , Cuthbertson Alan S.
Published: April 2023

Supplementary figure legends.
Supplementary Figure S3. Analysis of white blood cell and red blood cell counts from disseminated xenograft model. from In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia
Authors: Hagemann Urs B. , Wickstroem Katrine , Wang Ellen , Shea Adam O. , Sponheim Kristine , Karlsson Jenny , Bjerke Roger M. , Ryan Olav B. , Cuthbertson Alan S.
Published: April 2023

Blood samples from animals treated with vehicle and CD33-TTC, administered at the different dose levels, were taken at Day -1, Day 67 and Day 123. (A) White blood cell counts, expressed in 109/L. (B) Red blood cell counts, expressed in 1012/L.
Supplementary Figure S2. Flow cytometry analysis of CD33 antibody and CD33 antibody-chelator conjugate to HL-60 cells. from In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia
Authors: Hagemann Urs B. , Wickstroem Katrine , Wang Ellen , Shea Adam O. , Sponheim Kristine , Karlsson Jenny , Bjerke Roger M. , Ryan Olav B. , Cuthbertson Alan S.
Published: April 2023

Binding of CD33 antibody and CD33 antibody chelator-conjugate to CD33-positive HL-60 cells by FACS staining in comparison to an isotype control. Bound antibodies were detected using secondary PE-labeled anti-human antibody. Median fluorescence intensity (MFI) was recorded and plotted against antibody concentrations. EC50 values were determined by fitting data using Graph Pad software.
Supplementary Figures S1 and S2 from A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer
Authors: Bertino Erin M. , McMichael Elizabeth L. , Mo Xiaokui , Trikha Prashant , Davis Melanie , Paul Bonnie , Grever Michael , Carson William E. , Otterson Gregory A.
Published: April 2023

Figure S1. Serum cytokine analysis; Figure S2. Flow cytometric analysis of immune cell types.
Supplementary material, Figure Legends, Table 1 from Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC
Authors: Potter Danielle S. , Galvin Melanie , Brown Stewart , Lallo Alice , Hodgkinson Cassandra L. , Blackhall Fiona , Morrow Christopher J. , Dive Caroline
Published: April 2023

Materials and methods, Supplementary figure legends; Supplementary Table 1:BMX, MCL-1 and non-targeting siRNAs target sequence.
Supplementary Figure Legends from A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer
Authors: Bertino Erin M. , McMichael Elizabeth L. , Mo Xiaokui , Trikha Prashant , Davis Melanie , Paul Bonnie , Grever Michael , Carson William E. , Otterson Gregory A.
Published: April 2023

Legends for Supplementary figures S1 and S2
Supplementary Figure S6 from AKT Inhibition Promotes Nonautonomous Cancer Cell Survival
Authors: Solé Xavier , Alves Cleidson P. , Dey-Guha Ipsita , Ritsma Laila , Boukhali Myriam , Lee Ju H. , Chowdhury Joeeta , Ross Kenneth N. , Haas Wilhelm , Vasudevan Shobha , Ramaswamy Sridhar
Published: April 2023

Effect of microvesicle treatment in vitro on tumor cell proliferation in vivo
Supplementary Figure S5 from AKT Inhibition Promotes Nonautonomous Cancer Cell Survival
Authors: Solé Xavier , Alves Cleidson P. , Dey-Guha Ipsita , Ritsma Laila , Boukhali Myriam , Lee Ju H. , Chowdhury Joeeta , Ross Kenneth N. , Haas Wilhelm , Vasudevan Shobha , Ramaswamy Sridhar
Published: April 2023

Akti-1/2 microvesicles in vitro cross-cell line bioactivity assay
Sup Figure 2 from Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC
Authors: Potter Danielle S. , Galvin Melanie , Brown Stewart , Lallo Alice , Hodgkinson Cassandra L. , Blackhall Fiona , Morrow Christopher J. , Dive Caroline
Published: April 2023

Supplementary Figure 2. Cyotoxicity assays
Supplementary Figure S3 from AKT Inhibition Promotes Nonautonomous Cancer Cell Survival
Authors: Solé Xavier , Alves Cleidson P. , Dey-Guha Ipsita , Ritsma Laila , Boukhali Myriam , Lee Ju H. , Chowdhury Joeeta , Ross Kenneth N. , Haas Wilhelm , Vasudevan Shobha , Ramaswamy Sridhar
Published: April 2023

Effect of AKTi microvesicles on cell vitality and cell colony counts after exposure to stress conditions in vitro
Supplementary Figures 1 through 6 from Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma
Authors: Wang Jin , Chen Jianjun , Miller Duane D. , Li Wei
Published: April 2023

PDF - 476K, Figure S1. Establishment of vemurafenib-resistant A375 melanoma cell line A375RF21 from its parental A375 cell line using chronic selection over 3 months with increasing concentrations of vemurafenib; Figure S2. Anti-phospho-histone H3 and PI (propidium iodide) bivariate staining cell cycle analysis on vemurafenib-resistant cells; Figure S3. In vitro dose-response curves (n = 5) of each combination in A375 and A375RF21 cells; Figure S4. Major vemurafenib resistance mechanisms in A375RF21 cells are the over-expression of PDGFβ and the activations of the PI3K-AKT pathway; Figure S5. Effect of single agent and combination treatment on purified-protein based tubulin polymerization assay (n = 3); Figure S6. In vitro growth curve for A375 and vemurafenib-resistant subline A375RF21 cells.
Supplementary Dataset S2 from AKT Inhibition Promotes Nonautonomous Cancer Cell Survival
Authors: Solé Xavier , Alves Cleidson P. , Dey-Guha Ipsita , Ritsma Laila , Boukhali Myriam , Lee Ju H. , Chowdhury Joeeta , Ross Kenneth N. , Haas Wilhelm , Vasudevan Shobha , Ramaswamy Sridhar
Published: April 2023

Summary of GSEA results for GRO-Seq, RNA-Seq and protein datasets
Supplementary Figure 2 from Synthesis and Evaluation of the Novel Prostamide, 15-Deoxy, Δ12,14-Prostamide J2, as a Selective Antitumor Therapeutic
Authors: Ladin Daniel A. , Soliman Eman , Escobedo Rene , Fitzgerald Timothy L. , Yang Li V. , Burns Colin , Van Dross Rukiyah
Published: April 2023

15d-PMJ2 activity in murine NMSC cells
Supplementary Data from Inhibition of Isoprenylcysteine Carboxylmethyltransferase Induces Cell-Cycle Arrest and Apoptosis through p21 and p21-Regulated BNIP3 Induction in Pancreatic Cancer
Authors: Manu Kanjoormana Aryan , Chai Tin Fan , Teh Jing Tsong , Zhu Wan Long , Casey Patrick J. , Wang Mei
Published: April 2023

Supplementary Fig. S1. ICMT inhibitor treatment leads to reduced viability in sensitive pancreatic cancer cell lines. (A) MTS viability assay that measures the total viable cells (OD measured at 490 nm) at the time of initiation (0 hr) and end (48 hr) of cysmethynil treatment for multiple pancreatic cell lines. (B) IC50 of different cell lines in response to cysmethynil treatment, determined by MTS assay shown in (A). Supplementary Fig. S2. ICMT inhibitor induces p21 and LC3 expression independent of p53. (A) Immunoblot analysis of the indicated proteins in Miapaca2 cells after treatment with 0, 20 or 22.5 Î¼M cysmethynil for 48 h. (B) Immunoblot analysis of the indicated proteins in Miapaca2 cells with (siâ€�p53) or without (siâ€�control) p53 knockdown, and concurrent treatment with 0, 20, 22 and 24 Î¼M Cysmethynil. Supplementary Fig. S3. Forced expression of BCLâ€�XL rescues MiaPaca2 cells from apoptotic cell death induced by ICMT inhibition. (A) Light microscopy analysis of MiaPaca2 cells infected with either control retrovirus or that expressing BCLâ€�XL, with (+) or without (â€�) treatment with 22.5 Î¼M Cysmethynil for 48 h. (B) Flow cytometry assessment of the cell preparations from (A). Supplementary Fig. S4. Immunoblot study on the cell lysates prepared from AsPC1 and BxPC3 cells after 48 h treatment by either DMSO control or 22.5 Î¼M of cysmethynil.
Supplemental Table 1 from Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
Authors: Wagner Michael J. , Mitra Rahul , McArthur Mark J. , Baze Wallace , Barnhart Kirstin , Wu Sherry Y. , Rodriguez-Aguayo Cristian , Zhang Xinna , Coleman Robert L. , Lopez-Berestein Gabriel , Sood Anil K.
Published: April 2023

Primate urinalysis
Supplemental Figure 4 from Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
Authors: Wagner Michael J. , Mitra Rahul , McArthur Mark J. , Baze Wallace , Barnhart Kirstin , Wu Sherry Y. , Rodriguez-Aguayo Cristian , Zhang Xinna , Coleman Robert L. , Lopez-Berestein Gabriel , Sood Anil K.
Published: April 2023

Primate renal function and protein
Supplemental Figure 3 from Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
Authors: Wagner Michael J. , Mitra Rahul , McArthur Mark J. , Baze Wallace , Barnhart Kirstin , Wu Sherry Y. , Rodriguez-Aguayo Cristian , Zhang Xinna , Coleman Robert L. , Lopez-Berestein Gabriel , Sood Anil K.
Published: April 2023

Primate electrolytes and liver function tests
Supplemental Figure Legends from Apratoxin A Shows Novel Pancreas-Targeting Activity through the Binding of Sec 61
Authors: Huang Kuan-Chun , Chen Zhihong , Jiang Yimin , Akare Sandeep , Kolber-Simonds Donna , Condon Krista , Agoulnik Sergei , Tendyke Karen , Shen Yongchun , Wu Kuo-Ming , Mathieu Steven , Choi Hyeong-wook , Zhu Xiaojie , Shimizu Hajime , Kotake Yoshihiko , Gerwick William H. , Uenaka Toshimitsu , Woodall-Jappe Mary , Nomoto Kenichi
Published: April 2023

Figure S1. Synthesis of [3H]apratoxin A. Figure S2. Synthesis of C.18-epi-apratoxin A. Figure S3. Apratoxin A in vitro IC50 against panels of human cancer cell lines. Table S1. Summary table for in vivo efficacy studies. Figure S4. Apratoxin A concentration kinetics in plasma and various tissues in A549 human lung cancer xenograft tumor-bearing mice after a single IV dose (1 mg/kg). Figure S5. Apratoxin A and HUN-7293 have different binding sites on the Sec61 complex. Figure S6. Sec61α and Sec61β protein expression levels among different cell lines.
Supplemental Figure 1 from Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
Authors: Wagner Michael J. , Mitra Rahul , McArthur Mark J. , Baze Wallace , Barnhart Kirstin , Wu Sherry Y. , Rodriguez-Aguayo Cristian , Zhang Xinna , Coleman Robert L. , Lopez-Berestein Gabriel , Sood Anil K.
Published: April 2023

Primate Hematology
suppl. legends from PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
Authors: Engert Florian , Schneider Cornelius , Weiβ Lilly Magdalena , Probst Marie , Fulda Simone
Published: April 2023

Legends to supplemental Figures and Tables
suppl. Tab. 1 from PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
Authors: Engert Florian , Schneider Cornelius , Weiβ Lilly Magdalena , Probst Marie , Fulda Simone
Published: April 2023

IC50 cytotoxicity of PARP inhibitors
Supplementary Materials from Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis
Authors: Yang Jie , Qian Shihui , Cai Xueting , Lu Wuguang , Hu Chunping , Sun Xiaoyan , Yang Yang , Yu Qiang , Gao S. Paul , Cao Peng
Published: April 2023

Supplementary materials and methods
Supplementary Figure S3 from Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis
Authors: Yang Jie , Qian Shihui , Cai Xueting , Lu Wuguang , Hu Chunping , Sun Xiaoyan , Yang Yang , Yu Qiang , Gao S. Paul , Cao Peng
Published: April 2023

The relatively specific binding activity of CS-â…£a-Be with IL-6RÎ±
suppl. Fig. 1 from PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
Authors: Engert Florian , Schneider Cornelius , Weiβ Lilly Magdalena , Probst Marie , Fulda Simone
Published: April 2023

Cytotoxicity of PARP inhibitors and chemotherapeutics.
Supplementary Data from MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody
Authors: Farrell Pamela J. , Matuszkiewicz Jennifer , Balakrishna Deepika , Pandya Shweta , Hixon Mark S. , Kamran Ruhi , Chu Shaosong , Lawson J. David , Okada Kengo , Hori Akira , Mizutani Akio , Iwata Hidehisa , de Jong Ron , Hibner Barbara , Vincent Patrick
Published: April 2023

Supplemental Table 1. Activity of MET TKIs in enzyme and cellular assessments Supplemental Table 2. Activity of Compound 1 against approximately 130 additional protein kinases. Figure S1. Binding modes of selective MET TKIs. Figure S2. MET TKI, Compound 1, synergizes with in HGF antibody, TAK-701, resulting in enhanced antitumor efficacy in U-87MG glioblastomas. Figure S3. MET TKIs synergize with in HGF antibody, TAK-701, increasing overall survival. Figure S4. Inhibition of MET pathway signaling by Compound 1, TAK-701 and combination of Compound 1 + TAK-701, in U-87MG xenografts. Figure S5. Compound 1 synergizes with MEK or PI3K inhibitor resulting in enhanced loss of MKN45 cell viability.
Supplementary Figure S1 from Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis
Authors: Yang Jie , Qian Shihui , Cai Xueting , Lu Wuguang , Hu Chunping , Sun Xiaoyan , Yang Yang , Yu Qiang , Gao S. Paul , Cao Peng
Published: April 2023

MAPK and NF-ÎºB signaling are not involved in CS-â…£a-Be-induced breast cancer cell apoptosis
Supplementary Tables from Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues
Authors: Zhu Charles , Bandekar Amey , Sempkowski Michelle , Banerjee Sangeeta Ray , Pomper Martin G. , Bruchertseifer Frank , Morgenstern Alfred , Sofou Stavroula
Published: April 2023

Table S1. Effect of flow field in expression of PSMA by HUVEC cells in CCM. Table S2. Specific cell associated radioactivity delivered to PSMA+ HUVEC using different delivery constructs. Table S3. Viability of PSMA-positive and PSMA-negative HUVEC in monolayers after 10 hours treatment by the radiolabeled and non-radiolabeled Ab. Table S4. Nucleus absorbed dose as a function of cell geometry and emitter localization of homogeneously distributed Ac-225 excluding the emitted radioactive daughters. Table S5. Nucleus absorbed dose as a function of cell geometry and emitter localization of homogeneously distributed Ac-225 including the emitted radioactive daughters.
Figure S6 from Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma
Authors: Morgan Katherine M. , Fischer Bruce S. , Lee Francis Y. , Shah Jamie J. , Bertino Joseph R. , Rosenfeld Jeffrey , Singh Amartya , Khiabanian Hossein , Pine Sharon R.
Published: April 2023

Mechanisms of enhanced paclitaxel-induced apoptosis and proliferation inhibition by BMS-906024.
Figure S3 from Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues
Authors: Zhu Charles , Bandekar Amey , Sempkowski Michelle , Banerjee Sangeeta Ray , Pomper Martin G. , Bruchertseifer Frank , Morgenstern Alfred , Sofou Stavroula
Published: April 2023

Demonstration of enhanced expression of PSMA by HUVEC exposed to cell cultured media.
Figure S2 from Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma
Authors: Morgan Katherine M. , Fischer Bruce S. , Lee Francis Y. , Shah Jamie J. , Bertino Joseph R. , Rosenfeld Jeffrey , Singh Amartya , Khiabanian Hossein , Pine Sharon R.
Published: April 2023

Modulation of Notch1 activation by paclitaxel.
Supplementary Materials and Methods and Supplementary Figure Legends from Hypoxia-Regulated Overexpression of Soluble VEGFR2 Controls Angiogenesis and Inhibits Tumor Growth
Authors: Collet Guillaume , Lamerant-Fayel Nathalie , Tertil Magdalena , El Hafny-Rahbi Bouchra , Stepniewski Jacek , Guichard Alan , Foucault-Collet Alexandra , Klimkiewicz Krzysztof , Petoud Stéphane , Matejuk Agata , Grillon Catherine , Jozkowicz Alicja , Dulak Jozef , Kieda Claudine
Published: April 2023

PDF - 150KB, Supplementary Materials and Methods and legends for Supplementary Figures 1 through 6.
Supplementary Figure 5 from Hypoxia-Regulated Overexpression of Soluble VEGFR2 Controls Angiogenesis and Inhibits Tumor Growth
Authors: Collet Guillaume , Lamerant-Fayel Nathalie , Tertil Magdalena , El Hafny-Rahbi Bouchra , Stepniewski Jacek , Guichard Alan , Foucault-Collet Alexandra , Klimkiewicz Krzysztof , Petoud Stéphane , Matejuk Agata , Grillon Catherine , Jozkowicz Alicja , Dulak Jozef , Kieda Claudine
Published: April 2023

PDF - 3176KB, Characterization of B16F10 wt and msVEGFR2 expressing clones 13.3 and 16.4 tumors in vivo.
Supplementary Figure 4 from Hypoxia-Regulated Overexpression of Soluble VEGFR2 Controls Angiogenesis and Inhibits Tumor Growth
Authors: Collet Guillaume , Lamerant-Fayel Nathalie , Tertil Magdalena , El Hafny-Rahbi Bouchra , Stepniewski Jacek , Guichard Alan , Foucault-Collet Alexandra , Klimkiewicz Krzysztof , Petoud Stéphane , Matejuk Agata , Grillon Catherine , Jozkowicz Alicja , Dulak Jozef , Kieda Claudine
Published: April 2023

PDF - 2705KB, Expression of VEGFRs on the surface of B16F10-msVEGFR2 melanoma clone 13.3 and 16.4.
Supplementary Figure 8 from mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells
Authors: Koppenhafer Stacia L. , Goss Kelli L. , Terry William W. , Gordon David J.
Published: April 2023

Supplementary Figure 8 shows the effect of gemcitabine on the phosphorylation of 4E-BP1 in non-Ewing sarcoma cell lines.
Supplementary Figure 6 from mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells
Authors: Koppenhafer Stacia L. , Goss Kelli L. , Terry William W. , Gordon David J.
Published: April 2023

Supplementary Figure 6 shows the effect of drug treatments on mice weights in the xenograft experiments.
Supplementary Figure 5 from mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells
Authors: Koppenhafer Stacia L. , Goss Kelli L. , Terry William W. , Gordon David J.
Published: April 2023

Supplementary Figure 5 shows the effects of prexasertib on markers of apoptosis.
Supplementary Figure 4 from mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells
Authors: Koppenhafer Stacia L. , Goss Kelli L. , Terry William W. , Gordon David J.
Published: April 2023

Supplementary Figure 4 shows the effects of prexasertib on colony formation.
Supplementary Figure 3 from mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells
Authors: Koppenhafer Stacia L. , Goss Kelli L. , Terry William W. , Gordon David J.
Published: April 2023

Supplementary Figure 3 shows 4E-BP1 mRNA and protein levels in cell lines.
Supplementary Figure 2 from mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells
Authors: Koppenhafer Stacia L. , Goss Kelli L. , Terry William W. , Gordon David J.
Published: April 2023

Supplementary Figure 2 shows detection of protein synthesis using puromycin labeling.
Supplementary Figure 1 from mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells
Authors: Koppenhafer Stacia L. , Goss Kelli L. , Terry William W. , Gordon David J.
Published: April 2023

Supplementary Figure 1 shows knockdown of CHK1 using the siCHK1.pool siRNA.
Table S6 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
Authors: Hisamatsu Takeshi , McGuire Michael , Wu Sherry Y. , Rupaimoole Rajesha , Pradeep Sunila , Bayraktar Emine , Noh Kyunghee , Hu Wei , Hansen Jean M. , Lyons Yasmin , Gharpure Kshipra M. , Nagaraja Archana S. , Mangala Lingegowda S. , Mitamura Takashi , Rodriguez-Aguayo Cristian , Eun Young Gyu , Rose Johnathon , Bartholomeusz Geoffrey , Ivan Cristina , Lee Ju-Seog , Matsuo Koji , Frumovitz Michael , Wong Kwong K. , Lopez-Berestein Gabriel , Sood Anil K.
Published: April 2023

Nanostring miRNA data
figure S6 from A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity
Authors: Vega Mario I. , Shi Yijiang , Frost Patrick , Huerta-Yepez Sara , Antonio-Andres Gabriela , Hernandez-Pando Rogelio , Lee Jihye , Jung Michael E. , Gera Joseph F. , Lichtenstein Alan
Published: April 2023

Suppl fig 6: Immunocompetent non-tumor bearing mice injected IP daily with increasing concentrations of drug 3g for 21 days followed by harvest of serum for assays of alkaline phosphatase, ALT, AST, bilirubin and BUN. Chemistry values of control mice injected daily with DMSO (3g dose=0) were arbitrarily made '1'. Data are means+/-SD, N=4 mice/group.
figure S4 from A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity
Authors: Vega Mario I. , Shi Yijiang , Frost Patrick , Huerta-Yepez Sara , Antonio-Andres Gabriela , Hernandez-Pando Rogelio , Lee Jihye , Jung Michael E. , Gera Joseph F. , Lichtenstein Alan
Published: April 2023

Suppl fig 4: A) Mice were challenged with 8226 cells (admixed with Matrigel) SC and, when tumor size was 300mm3, mice were randomized to receive drug 3g at 5 mg/kg IP daily (X) for 9 days or DMSO (o); Results shown are mean +/- SD tumor volume,n=8 mice/group. The tumor growth was significantly slowed (p<0.05) by treatment with 3g. B) Individual mouse tumor growth curves for the experiment shown in figure 5C. C) SQ-tumor-challenged mice treated daily with DMSO or either drug 3g or NSC126405, 20mg/kg IP for 9 days. Results are tumor volume, mean+/-SD, n=8mice/group; D) Survival curves from experiment shown in "C". E) Weights of IV-tumor-challenged mice treated with DMSO or drug 3g at 5mg/kg or 10mg/kg presented as mean+/-SD.
figure S3 from A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity
Authors: Vega Mario I. , Shi Yijiang , Frost Patrick , Huerta-Yepez Sara , Antonio-Andres Gabriela , Hernandez-Pando Rogelio , Lee Jihye , Jung Michael E. , Gera Joseph F. , Lichtenstein Alan
Published: April 2023

Supplemental figure 3: Mice were challenged SQ with 8226 MM cells and, when tumors were 500mm3 mice were treated with DMSO(control) or drug 3g at 20mg/kg by daily IP injection (4 mice/group). Data are tumor volume at days 2, 3 or 4 after starting treatment, mean+/-SD.
Supplemental Figures 1-5 from Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP
Authors: Wang Rui , He Yupeng , Robinson Valerie , Yang Ziping , Hessler Paul , Lasko Loren M. , Lu Xin , Bhathena Anahita , Lai Albert , Uziel Tamar , Lam Lloyd T.
Published: April 2023

Suppl. Figure 1. Dependency of human melanoma cell lines on MITF; Suppl. Figure 2. A-485 treatment reduces viability of primary melanoma cell line; Suppl. Figure 3. A-485 treatment does not induce apoptosis in melanoma cells; Suppl. Figure 4. A-485 treatment does not increase invasiveness in melanoma cells; Suppl. Figure 5. MITF gene expression and copy number is associated with A-485-induced senescence
Supplementary Tables and Figures from Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms
Authors: Scott Aaron J. , Arcaroli John J. , Bagby Stacey M. , Yahn Rachel , Huber Kendra M. , Serkova Natalie J. , Nguyen Anna , Kim Jihye , Thorburn Andrew , Vogel Jon , Quackenbush Kevin S. , Capasso Anna , Schreiber Anna , Blatchford Patrick , Klauck Peter J. , Pitts Todd M. , Eckhardt S. Gail , Messersmith Wells A.
Published: April 2023

Supplemental Table 1: Molecular and clinical characteristics of the 10 CRC explants used in the PDX model experiments. Seven explants have a KRAS mutation, 4 have a PIK3CA mutation, and none have a BRAF mutation. Over half of the explants came from patients who had previously received treatment for mCRC. Supplemental Table 2: Using DCE-MRI measurements, treatment with cabozantinib demonstrated significant decrease in vascularity on day 28 compared to baseline and day 7. Regorafenib treatment did not demonstrate a decrease in vascularity. Supplemental Table 3: [18F] FDG-PET imaging revealed significantly reduced FDG avidity on days 7 and days 28 of cabozantinib treatment compared to baseline, whereas FDG avidity did not diminish in the regorafenib treated explants. Supplemental Table 4: To better understand the potential metabolic effects of cabozantinib, we analysed signalling pathways involved in metabolism using the KEGG database. Receptor tyrosine kinase (RTK) assay revealed a decrease in many of the pathways responsible for cell metabolism after 3 days of cabozantinib treatment in three of the sensitive CRC explants. Supplemental Figure 1: Cabozantinib and regorafenib treatment in a Humanized HGF mouse model. Cabozantinib had greater antitumor effects when compared to regorafenib in the hHGF scid mice in CRC203 and CRC020. Similar results were observed when compared to athymic nude mice for CRC203 (REG TGII: 39.3, Cabo TGII: 14.93) and CRC020 (REG TGII: 17.5, Cabo TGII: -5.68). Supplemental Figure 2: Changes in TIE2 and VEGFR2 expression were variable and did not demonstrate a sustained decrease after treatment with regorafenib. Supplemental Figure 3: After 7 days of regorafenib treatment, there was no significant reduction in activation of p-AXL, AKT, and pS6 compared to control, and there was a variable trend in p-MET and p-RET levels as measured by RTK assay. Supplemental Figure 4: Regorafenib treatment led to decreased ATG3, LC3A/B, and beclin-1 in the CRC098 explant; however, levels of these enzymes increased in the CRC162 explant. Supplemental Figure 5: In vitro analysis of caspase 3/7 expression in cell lines HCT116 (a, c) and HT29 (b, d) after cabozantinib and crizotinib treatment showed significant increase in autophagy index relative to control*** and to regorafenib###. Caspase 3/7 expression was measured via fluorescence using the CYTO-ID® Autophagy Detection Kit. Crizotinib combined with SBI-020695, an anti-ULK-1 agent, did not result in increased caspase 3/7 expression, whereas caspase 3/7 expression significantly increased with cabozantinib plus SBI-020695.
Supplementary Table S1 from Involvement of Prokineticin 2–expressing Neutrophil Infiltration in 5-Fluorouracil–induced Aggravation of Breast Cancer Metastasis to Lung
Authors: Sasaki Soichiro , Baba Tomohisa , Muranaka Hayato , Tanabe Yamato , Takahashi Chiaki , Matsugo Seiichi , Mukaida Naofumi
Published: April 2023

Supplementary Table S1
Supplementary Figure S8. from Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer
Authors: Singh Krishna B. , Ji Xinhua , Singh Shivendra V.
Published: April 2023

Effect of LLM treatment on body weights of mice.
Supplementary Material from Involvement of Prokineticin 2–expressing Neutrophil Infiltration in 5-Fluorouracil–induced Aggravation of Breast Cancer Metastasis to Lung
Authors: Sasaki Soichiro , Baba Tomohisa , Muranaka Hayato , Tanabe Yamato , Takahashi Chiaki , Matsugo Seiichi , Mukaida Naofumi
Published: April 2023

Supplementary Methods
Supplementary Figure S5. from Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer
Authors: Singh Krishna B. , Ji Xinhua , Singh Shivendra V.
Published: April 2023

Densitometric quantitation of PSA protein expression in 22Rv1, LNCaP, and C4-2B cells (for data shown in Fig. 2E of the main text).
Supplementary Figure S4. from Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer
Authors: Singh Krishna B. , Ji Xinhua , Singh Shivendra V.
Published: April 2023

LLM treatment inhibited R1881-stimulated nuclear translocation of AR in LNCaP cells.
Supplementary Figure S3. from Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer
Authors: Singh Krishna B. , Ji Xinhua , Singh Shivendra V.
Published: April 2023

Densitometric quantitation of immunoblots for AR, AR splice variants, AR-V7, and phospho-AR (Ser213/210) in 22Rv1, LNCaP, and C4-2B cells (for data shown in Fig. 2A of the main text).
Supplementary Tables S1-S9 from A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics
Authors: Quist Jelmar , Mirza Hasan , Cheang Maggie C.U. , Telli Melinda L. , O'Shaughnessy Joyce A. , Lord Christopher J. , Tutt Andrew N.J. , Grigoriadis Anita
Published: April 2023

Supplementary Table S1: Overview of the TNBC616 cohort. Supplementary Table S2: Overview of all cohorts, including the number of TNBCs, doi and accessions. Supplementary Table S3: List of gene sets identified by CONEXIC in Guy's TNBC. Supplementary Table S4: List of gene sets identified by CONEXIC in METABRIC TNBC. Supplementary Table S5: Table of modulatory genes identified by CONEXIC in Guy's TNBC. Supplementary Table S6: Table of modulatory genes identified by CONEXIC in METABRIC TNBC. Supplementary Table S7: List of significantly enriched GO biological processes in Guy's-set 33. Supplementary Table S8: List of significantly enriched GO biological processes in METABRIC-set 15. Supplementary Table S9: List of significantly enriched GO biological processes in Guy's-set 27.
Supplementary Figure S2. from Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer
Authors: Singh Krishna B. , Ji Xinhua , Singh Shivendra V.
Published: April 2023

Effects of LLM and/or R1881 treatments on proliferation of LNCaP and C4-2B cells.
Supplementary Information from A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics
Authors: Quist Jelmar , Mirza Hasan , Cheang Maggie C.U. , Telli Melinda L. , O'Shaughnessy Joyce A. , Lord Christopher J. , Tutt Andrew N.J. , Grigoriadis Anita
Published: April 2023

Supplementary Information: Extended methods.
Supplementary Figure S4 from A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics
Authors: Quist Jelmar , Mirza Hasan , Cheang Maggie C.U. , Telli Melinda L. , O'Shaughnessy Joyce A. , Lord Christopher J. , Tutt Andrew N.J. , Grigoriadis Anita
Published: April 2023

Supplementary Figure S4: Barplot representing sensitivity to CCT007093, a small molecule PPM1D inhibitor in TNBC cell line models.
Supplementary Figure S3 from A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics
Authors: Quist Jelmar , Mirza Hasan , Cheang Maggie C.U. , Telli Melinda L. , O'Shaughnessy Joyce A. , Lord Christopher J. , Tutt Andrew N.J. , Grigoriadis Anita
Published: April 2023

Supplementary Figure S3: Molecular characterisation of the MC6 subtype in six TNBC cohorts.
Supplementary Figure S2 from A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics
Authors: Quist Jelmar , Mirza Hasan , Cheang Maggie C.U. , Telli Melinda L. , O'Shaughnessy Joyce A. , Lord Christopher J. , Tutt Andrew N.J. , Grigoriadis Anita
Published: April 2023

Supplementary Figure S2: Classification of TNBC cohorts using the Guy's-set 33 decision tree.
Supplementary Figure S1 from A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics
Authors: Quist Jelmar , Mirza Hasan , Cheang Maggie C.U. , Telli Melinda L. , O'Shaughnessy Joyce A. , Lord Christopher J. , Tutt Andrew N.J. , Grigoriadis Anita
Published: April 2023

Supplementary Figure S1: Boxplots depicting the association between gene expression levels (y-axis) and copy number status (x-axis) for each of the modulatory genes.
Supplementary figure legends from Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer
Authors: Xu Sen , Yang Zongyuan , Jin Ping , Yang Xin , Li Xiaoting , Wei Xiao , Wang Ya , Long Sixiang , Zhang Taoran , Chen Gang , Sun Chaoyang , Ma Ding , Gao Qinglei
Published: April 2023

Revised Supplementary figure legends
Supplementary Methods, Figures S1-S11, and References from A Chemical Modulator of p53 Transactivation that Acts as a Radioprotective Agonist
Authors: Morita Akinori , Takahashi Ippei , Sasatani Megumi , Aoki Shin , Wang Bing , Ariyasu Shinya , Tanaka Kaoru , Yamaguchi Tetsuji , Sawa Akiko , Nishi Yurie , Teraoka Tatsuro , Ujita Shohei , Kawate Yosuke , Yanagawa Chihiro , Tanimoto Keiji , Enomoto Atsushi , Nenoi Mitsuru , Kamiya Kenji , Nagata Yasushi , Hosoi Yoshio , Inaba Toshiya
Published: April 2023

Figure S1. 5CHQ suppresses etoposide-induced apoptosis in wt-p53-expressing cells; Figure S2. Effect of 5CHQ on p53's DNA-binding to CDKN1A and BBC3 promoter oligonucleotides; Figure S3. 5CHQ by itself activates p53-mediated transcription; Figure S4. Effect of 5CHQ on cell cycle distribution; Figure S5. MTD study of 5CHQ; Figure S6. The technique of SBI to avoid BM aplasia; Figure S7. Additional TBI experiments; Figure S8. Sixty-day survival test of C57BL/6 mouse after 20 Gy-SBI; Figure S9. Immunoblotting also revealed the transactivation-modulating activity of 5CHQ; Figure S10. Dose response of 5CHQ on etoposide-induced apoptosis in FM3A cells; Figure S11. 5CHQ relieves the decrease of the stem cell marker Lgr5 mRNA expression after SBI.
Figure S3 from Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer
Authors: Xu Sen , Yang Zongyuan , Jin Ping , Yang Xin , Li Xiaoting , Wei Xiao , Wang Ya , Long Sixiang , Zhang Taoran , Chen Gang , Sun Chaoyang , Ma Ding , Gao Qinglei
Published: April 2023

Metformin mediated NF-κB/IL6 signaling independent of the AMPK pathway, related to Figure 3.
Figure S2 from Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer
Authors: Xu Sen , Yang Zongyuan , Jin Ping , Yang Xin , Li Xiaoting , Wei Xiao , Wang Ya , Long Sixiang , Zhang Taoran , Chen Gang , Sun Chaoyang , Ma Ding , Gao Qinglei
Published: April 2023

Metformin priming the primary CAFs attenuated the IL6 expression and the CM-facilitated tumor growth, related to Figure 2.
Supplementary Table 1. Supplementary Figures 1 and 2. from Intratumoral Payload Concentration Correlates with the Activity of Antibody–Drug Conjugates
Authors: Zhang Donglu , Yu Shang-Fan , Khojasteh S. Cyrus , Ma Yong , Pillow Thomas H. , Sadowsky Jack D. , Su Dian , Kozak Katherine R. , Xu Keyang , Polson Andrew G. , Dragovich Peter S. , Hop Cornelis E.C.A.
Published: April 2023

Table S1. (A) Quantitation of PBD in tumors and (B) total antibody in plasma of xenograft mice following intravenously administration of ADC conjugates. Figure S1. (A-D) Correlation (X-Y plots) of tumor growth inhibition with intratumor PBD exposures after intravenous administration of corresponding ADCs A1-A4. Figure S2. Disulfide stability and immolation for payload release in incubations of ADCs A1-A4 in the presence of cysteine at pH 5.5 or 7.0.
Table S2 from PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma
Authors: Brunen Diede , de Vries Romy C. , Lieftink Cor , Beijersbergen Roderick L. , Bernards René
Published: April 2023

Results from the CRISPR screen
Supplementary Figure 2 from Clinical Application of Circulating Tumor DNA in the Genetic Analysis of Patients with Advanced GIST
Authors: Xu Hao , Chen Liang , Shao Yang , Zhu Dongqin , Zhi Xiaofei , Zhang Qiang , Li Fengyuan , Xu Jianghao , Liu Xisheng , Xu Zekuan
Published: April 2023

Correlation between tumor size, Ki-67 and positive rate of ctDNA mutation.
Supplemental table 1 from PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma
Authors: Brunen Diede , de Vries Romy C. , Lieftink Cor , Beijersbergen Roderick L. , Bernards René
Published: April 2023

Patient characteristics of the neuroblastoma cohorts studied here.
Supplementary Figure 1 from Clinical Application of Circulating Tumor DNA in the Genetic Analysis of Patients with Advanced GIST
Authors: Xu Hao , Chen Liang , Shao Yang , Zhu Dongqin , Zhi Xiaofei , Zhang Qiang , Li Fengyuan , Xu Jianghao , Liu Xisheng , Xu Zekuan
Published: April 2023

Imatinib dosages and operation treatment.
Supplemental figure 6. AZD1208 suppresses in vivo growth of KELLY cells from PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma
Authors: Brunen Diede , de Vries Romy C. , Lieftink Cor , Beijersbergen Roderick L. , Bernards René
Published: April 2023

(A-C) KELLY cells (1.106 cells) were subcutaneously implanted in NMRI mice. Once tumors were established (80mm3), animals were treated with vehicle or AZD1208 (90 mg/kg). Each line represents one tumor. (D) KELLY cells (5.106 cells) were subcutaneously implanted in NMRI mice. Once tumors were established (200mm3), animals were treated with vehicle or AZD1208 (30 mg/kg). Each line represents one tumor. (E) Body weight of mice injected with gNT KELLY cells and treated with vehicle or 90 mg/kg AZD1208. (F) High PIM mRNA expression correlates with poor overall survival in NF1 expressing neuroblastoma. Kaplan-Meier survival curve of the Kocak cohort demonstrate overall patient survival, using median PIM expression as a cut-off value for high versus low PIM expression. High PIM1/2/3 indicates patients with high expression of either PIM1, -2, or -3. High NF1 expression was determined using the 25% percentile as a cut-off. P-values were calculated using a log-rank test.
Supplemental figure 4. NF1 knockout induces PIM inhibitor resistance from PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma
Authors: Brunen Diede , de Vries Romy C. , Lieftink Cor , Beijersbergen Roderick L. , Bernards René
Published: April 2023

(A-B) NF1 loss results in PIM inhibitor resistance in a colony formation assay. SK-N-SH cells were plated in 6-well plates and treated with increasing concentrations of AZD1208 or PIM-447. Drug-containing medium was refreshed every 3 days. Cells were fixed, stained, and scanned when untreated wells of each particular cell line reached confluency (n=3). (C-D) NF1 knockout results in enhanced MAPK and AKT signaling and sustained mTOR signaling upon PIM inhibition. SH-SY5Y and SK-N-SH cell lines were treated with 2 μM AZD1208 for 0, 24, and 48 hours followed by western blot analysis (n=3).
Table S1 from Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105
Authors: Liu Yingmiao , Starr Mark D. , Brady John C. , Rushing Christel , Pang Herbert , Adams Bonne , Alvarez Delia , Theuer Charles P. , Hurwitz Herbert I. , Nixon Andrew B.
Published: April 2023

patients characteristics
Figure S1 from Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105
Authors: Liu Yingmiao , Starr Mark D. , Brady John C. , Rushing Christel , Pang Herbert , Adams Bonne , Alvarez Delia , Theuer Charles P. , Hurwitz Herbert I. , Nixon Andrew B.
Published: April 2023

Dendrograms
Supplemental figure 2. PIM kinases are a potential therapeutic target in neuroblastoma from PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma
Authors: Brunen Diede , de Vries Romy C. , Lieftink Cor , Beijersbergen Roderick L. , Bernards René
Published: April 2023

(A-B) Knockdown levels of PIM1, -2, and -3. KELLY and SH-SY5Y cell lines were transfected with scrambled siRNA (siCTRL) or siRNAs targeting PIM1, -2, or -3, cultured for 2 days, followed by RNA isolation and qRT (n=3). (C-D) Neuroblastoma cell lines demonstrate differential sensitivity to AZD1208 in a short-term assay. Cells were plated in 384-well plates, treated for 5 days with increasing concentrations of AZD1208, and viability was measured using CellTiter-Blue (n=3). (E-F) Neuroblastoma cell lines demonstrate differential sensitivity to PIM-447 in a colony formation assay. Cells were plated in 6-well plates and treated with increasing concentrations of AZD1208. Drug-containing medium was refreshed every 3 days. Cells were fixed, stained, and scanned when untreated wells reached confluency (n=3). (G) PIM-447-resistant cell lines demonstrate sustained mTOR signaling upon treatment. Cells were treated with 2 μM PIM-447 for 0, 24, and 48 hours followed by western blot analysis (n=3).
Supplemental figure 1. PIM expression and overall survival Versteeg cohort from PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma
Authors: Brunen Diede , de Vries Romy C. , Lieftink Cor , Beijersbergen Roderick L. , Bernards René
Published: April 2023

(A-D) High PIM2 and -3 mRNA expression correlates with poor overall survival in neuroblastoma. Kaplan- Meier survival curves of the Versteeg cohort (88 patients) demonstrate overall patient survival, using median PIM expression as a cut-off value for high versus low expression. High PIM1/2/3 indicates patients with high expression of either PIM1, -2, or -3. P-values were calculated using a log-rank test. (E-G) PIM expression across tumor stages (Versteeg cohort). P-values were calculated using a one-way ANOVA and Dunnett''s test. p {less than or equal to} 0.05 (*) (H) PIM expression in MYCN amplified and non-amplified tumors (Versteeg cohort). P-values were calculated using an unpaired T-test. p {less than or equal to} 0.001 (***)
Table S2 from Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy
Authors: Peyser Brian D. , Hermone Ann , Salamoun Joseph M. , Burnett James C. , Hollingshead Melinda G. , McGrath Connor F. , Gussio Rick , Wipf Peter
Published: April 2023

One-dose NCI-60 results for compound 1 with DCNP.
Table S1 from Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy
Authors: Peyser Brian D. , Hermone Ann , Salamoun Joseph M. , Burnett James C. , Hollingshead Melinda G. , McGrath Connor F. , Gussio Rick , Wipf Peter
Published: April 2023

SI for publicly released NCI-60 data.